The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
Prostate cancer is the most common cancer, and the second leading cause of death from cancer, in males in most Western countries. Advanced prostate cancer is initially sensitive to androgen deprivation therapy, but usually progresses to the castration-resistant state. There is now incontrovertible evidence that castration-resistant prostate cancer (CRPC) remains hormone driven, with intratumoral steroid synthesis fueling tumor growth. Several novel agents targeted androgen receptor signaling are currently being evaluated including abiraterone and MDV3100. Recent results of the phase III trial of abiraterone acetate in post-docetaxel patients has shown an overall survival benefit in advanced CRPC. This new treatment is likely to become a new standard of care for patients with metastatic CRPC.
Written by:
Zivi A, Massard C, De-Bono J. Are you the author?
Reference: Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22.
doi: 10.3816/CGC.2010.n.003
PubMed Abstract
PMID: 21208851
UroToday.com Prostate Cancer Section
